A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3K Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Brief Summary

Type:
Myelofibrosis

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04551053

Study #:
STUDY00146669

Start Date:
Aug 08, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04551053

View Complete Trial Details & Eligibility at ClinicalTrials.gov